Bioprocess Analyzers Market - By Product, By Analysis Type, By Application, By End Use - Global Forecast, 2026 - 2035

Bioprocess Analyzers Market Size

The global bioprocess analyzers market size was valued at USD 2.5 billion in 2025 and is projected to grow from USD 2.8 billion in 2026 to USD 7.8 billion by 2035, expanding at a CAGR of 12.2%, according to the latest report published by Global Market Insights Inc. This substantial growth is driven by numerous factors such as growing demand for biopharmaceutical products, advancements in biotechnology and bioprocessing, increasing demand for biosimilars, and rising government initiatives and funding.

The bioprocess analyzers consist of specialized tools that help monitor and measure essential parameters throughout the  biopharmaceutical manufacturing process for compliance with regulatory requirements while ensuring that the products produced maintain both quality and efficacy. Some of the more prominent manufacturers of market include F. Hoffmann-La Roche Ltd., Sartorius AG, Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies, Inc.  Major companies in market are growing their market presence by diversifying  product offerings to include more sophisticated solutions for real-time analysis and analytics to adapt to the changing needs of the biopharmaceutical industry.
 

The market grew from USD 1.8 billion in 2022 to USD 2.3 billion in 2024. The growing demand for biopharmaceutical products is a significant driver for the bioprocess analyzer market. As the global population increases and chronic diseases such as cancer, diabetes, and cardiovascular disorders become more prevalent, there is a shift toward advanced biopharmaceutical therapies that offer targeted and personalized treatment options. These therapies require precise control of production processes to ensure safety, efficacy, and compliance, which in turn boosts the adoption of bioprocess analyzers for real-time monitoring of substrates, metabolites, and product concentrations. According to the World Health Organization (WHO), noncommunicable diseases (NCDs) account for 41 million deaths annually, representing 74% of global mortality. Cardiovascular diseases alone cause 17.9 million deaths each year, followed by cancers, chronic respiratory diseases, and diabetes. This alarming burden of NCDs is driving pharmaceutical companies to invest heavily in biologics and biosimilars, creating a strong need for advanced analytical tools. Bioprocess analyzers enable manufacturers to maintain high-quality standards and optimize yields, making them indispensable in meeting the growing demand for biopharmaceutical products worldwide.
 

Additionally, rising government initiatives and funding are playing a pivotal role in accelerating the adoption of bioprocess analyzers across the biopharmaceutical industry. Governments worldwide are channeling substantial resources into research programs, infrastructure development, and public-private partnerships to strengthen bioprocessing capabilities. Such initiatives create a favorable environment for manufacturers to integrate high-performance analyzers that support real-time monitoring and compliance with stringent quality standards.
 

For instance, the National Institute of General Medical Sciences (NIGMS), part of the NIH, allocated a FY 2023 budget of USD 3.2 billion to support foundational research that advances biological process understanding and improves disease diagnosis and treatment. Similarly, the European Union’s Horizon 2020 program invested EURO 80 billion between 2014 and 2020 to foster research collaboration and technological innovation. By creating a strong foundation for research, infrastructure, and innovation, these programs are driving biopharmaceutical companies to integrate cutting-edge analytical tools for real-time monitoring and process optimization, thereby expanding the market for bioprocess analyzers globally.
 

Bioprocess analyzers are used to monitor and control critical parameters during biopharmaceutical production, such as substrate levels, metabolite concentrations, and product quality. They enable real-time analysis in processes like fermentation and cell culture, ensuring optimal conditions for cell growth and protein expression. These analyzers support applications in biologics, biosimilars, and vaccine manufacturing by improving process efficiency, reducing variability, and maintaining compliance with regulatory standards. Bioprocessing analyzers allow for quick assessment during fermentation and cell culture procedures in order to enable the best conditions for cell and protein growth.
 

Bioprocess Analyzers Market Trends

• Advancements in biotechnology and bioprocessing have become a critical driver for the market, significantly enhancing the precision, speed, and automation of analytical systems tailored for real-time biopharmaceutical production.
   
• These innovations have enabled a shift from conventional offline testing toward integrated at-line and inline solutions, facilitating continuous, non-invasive analysis of substrates, metabolites, and product concentrations directly within bioreactors, thereby reducing process variability and improving yield.
   
• A cornerstone of this evolution is the integration of process analytical technology (PAT) frameworks, which allow predictive control and automated feedback loops for process optimization. For instance, the Merck ProCellics Raman Analyzer, equipped with Bio4C PAT software, offer inline Raman spectroscopy to monitor multiple critical parameters like glucose and lactate in real time without sampling.
   
• Integration of real-time, inline sensing and automation for process control have further improved process consistency. For instance, Sartorius’s BioPAT Trace system uses online enzymatic amperometric sensors to continuously monitor glucose and lactate across multiple vessels, enabling automated feed/bleed control for consistent performance. In parallel, Hamilton’s new GlucoSense sensor delivers real-time, in situ glucose measurement directly within cell culture environments, matching the reliability of pH or dissolved oxygen probes and simplifying calibration for R&D to GMP applications.
   
• The impact of cloud-based platforms and AI-driven analytics has been equally transformative, allowing seamless integration of large data sets, predictive modeling, and trend analytics for proactive decision-making. Together, these technologies make bioprocess analyzers essential for modern biomanufacturing, helping produce biologics more efficiently and supporting advanced treatments like precision and personalized medicine.
   

Bioprocess Analyzers Market Analysis  

Based on product, the market is segmented into instruments and consumables and accessories. The consumables and accessories segment dominated the market with the largest revenue of USD 1.4 billion in 2025 and is expected to grow at a lucrative CAGR of 12.1% over the forecast period.
 

• Consumables and accessories play a critical role in the market by ensuring seamless operation, compliance, and efficiency in biopharmaceutical production. It includes disposable sensors, sample tubes, filters, calibration kits, and analytical reagents which support real-time monitoring and maintain process integrity.
   
• The growing adoption of automation and continuous bioprocessing has significantly increased the demand for analyzer-compatible consumables, as they enable high-throughput workflows and reduce manual intervention. For instance, Thermo Fisher Scientific’s Nalgene Sample Tubes are engineered for automated sampling systems, offering compatibility with high-throughput processes and improving operational efficiency.
   
• Additionally, stringent regulatory requirements in biopharmaceutical manufacturing drive the need for specialized consumables that support regular calibration and validation of analyzers, ensuring compliance with GMP and PAT standards.
   
• These ongoing advancements and the rising complexity of biologics production are key factors fuelling the demand for bioprocess analyzer consumables and accessories, thereby propelling market growth.
   

Based on analysis type, the bioprocess analyzers market is segmented into substrate analysis, metabolite analysis, and concentration detection. The concentration detection segment dominated the market with the largest revenue of USD 1.3 billion in 2025 and is expected to grow at a lucrative CAGR of 12.2% over the forecast period. 
 

• The concentration detection segment in bioprocess analyzers focuses on technologies that accurately measure the concentration of critical components such as proteins, antibodies, and other biologics during production. These systems utilize advanced analytical techniques like UV-Vis spectroscopy, Raman spectroscopy, and variable pathlength technology to provide precise, real-time measurements without extensive sample preparation.
   
• Demand for concentration detection solutions is increasing as biopharmaceutical companies strive to optimize yields and reduce batch failures in biologics and biosimilars production. These analyzers are widely used in upstream and downstream processes, including fermentation, cell culture, and purification, where accurate concentration data is essential for process control and quality assurance.
   
• The growing complexity of biologics and personalized therapies has further reinforced the need for advanced concentration detection systems that can deliver rapid and reliable results. A notable example is Repligen’s CTech SoloVPE system, which offers dilution-free protein concentration measurements in under 30 seconds, streamlining workflows and improving operational efficiency. This technology enables manufacturers to monitor critical quality attributes without manual intervention, supporting automated and high-throughput bioprocessing environments.
   
• With advancements in automation and integration with process analytical technology (PAT) frameworks, concentration detection technologies are expected to see widespread adoption in market.
   

Based on application, the bioprocess analyzers market is segmented into antibiotics, recombinant proteins, biosimilars, and other applications. The recombinant proteins segment held a significant revenue share of 36% in 2025 and is expected to grow at a CAGR of 12.1% over the forecast period.
 

• Recombinant proteins play a vital role in therapies for cancer, autoimmune conditions, and metabolic disorders, making stringent control over their quality and purity essential. Bioprocess analyzers provide real-time tracking of key parameters such as substrate utilization, metabolite buildup, and protein concentration throughout fermentation and cell culture processes, ensuring optimal conditions for expression and maximizing yield of these proteins.
   
• Demand for recombinant proteins continues to rise due to their role in targeted therapies and the growing prevalence of chronic diseases. Manufacturers rely on advanced analyzers to maintain stringent process control, reduce variability, and comply with regulatory standards like GMP and PAT.
   
• A notable example is Agilent Technologies’ ProteoAnalyzer System, which uses automated parallel capillary electrophoresis (CE SDS) to rapidly analyze recombinant proteins, including monoclonal antibodies, biosimilars, and purification fractions.
   
• By enabling faster, more accurate analysis of recombinant proteins and supporting high-throughput production, these technologies empower manufacturers to scale operations efficiently, thereby increasing market growth.
   

Based on end use, the bioprocess analyzers market is segmented into biopharmaceutical companies, CROs and CMOs, research and academic institutes, and other end users. The biopharmaceutical companies segment dominated the market with the largest revenue share of 44.2% in 2025 and is expected to grow at the significant CAGR over the forecast period.
 

• Biopharmaceutical companies form the largest end user segment for bioprocess analyzers, as these organizations are responsible for producing complex biologics such as monoclonal antibodies, recombinant proteins, and biosimilars.
   
• The growing global demand for biologics and personalized therapies has pushed biopharmaceutical companies to adopt advanced technologies, including automation and continuous bioprocessing.
   
• Leading biopharmaceutical firms are also investing in high-throughput and inline analytical solutions to support large-scale manufacturing and flexible production models. Technologies such as Raman spectroscopy, UV-Vis variable pathlength systems, and multi-parameter sensors allow continuous monitoring without manual sampling, minimizing contamination risks and enhancing compliance.
   
• As biopharmaceutical companies expand global manufacturing capabilities and focus on next-generation therapies, the demand for bioprocess analyzers will continue to grow, further supporting market growth.
   

North America Bioprocess Analyzers Market

North America dominated the global market with a market share of 37.8% in 2025.
 

• The U.S. market was valued at USD 627.3 million and USD 701.4 million in 2022 and 2023, respectively. In 2025, the market size reached USD 860.2 million from USD 776.4 million in 2024. U.S. dominates the market in North America, primarily driven by the rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders. This surge in biologics and personalized medicine demand underscores the need for advanced analyzers to ensure production efficiency, quality, and regulatory compliance. For example, the Global Cancer Observatory reported that in 2022, the U.S. accounted for 89.1% of cancer cases in the region, while Canada represented 10.9%, highlighting the scale of therapeutic requirements.
   
• Significant R&D investments further accelerate market growth, with PhRMA members spending approximately USD 96 billion globally on R&D in 2023. The expansion of biomanufacturing capabilities, stringent regulatory standards, and integration of digital health and data analytics are fostering adoption of high-performance analyzers. These technologies enable precise monitoring, enhanced data management, and process optimization, supporting North America’s leadership in market.
   

Europe Bioprocess Analyzers Market

Europe bioprocess analyzers accounted for USD 762.3 million in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• Escalating demand for biopharmaceutical products particularly monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies is driving significant growth in Europe’s bioprocess analyzer market. The rising prevalence of chronic diseases and the adoption of personalized medicine have created a strong need for precise and efficient bioprocessing solutions. According to European Medicines Agency, more than 1,200 biopharmaceutical products are currently in clinical development across the region, and in 2023, regulators approved 77 new medicines, including 39 novel active substances. Bioprocess analyzers play a critical role in ensuring production efficiency, maintaining quality standards, and meeting stringent regulatory requirements.
   
• Government and private-sector investments in research and development further strengthen this market. Public R&D funding (GBARD) reached EURO 127.9 billion in 2024, representing 0.71% of EU GDP and marking a 59% increase since 2014. Pharmaceutical industry R&D spending in the EU and partner countries grew from EURO 27.8 billion to EURO 46.2 billion between 2010 and 2022, at an annual growth rate of 4.4%. Initiatives such as Horizon Europe and targeted biotech programs are accelerating innovation in bioprocessing technologies. The integration of digital health, advanced data analytics, and continuous manufacturing platforms is enhancing process optimization and compliance, positioning Europe as growing region in market.
   

Germany bioprocess analyzers market is projected to experience steady growth between 2026 and 2035.
 

• The Germany market is witnessing robust growth, primarily driven by the rising demand for biosimilars. As healthcare providers and pharmaceutical companies increasingly adopt cost-effective alternatives to biologics, the need for advanced analytical tools to ensure quality, consistency, and regulatory compliance has surged. Bioprocess analyzers play a critical role in monitoring parameters such as pH, dissolved oxygen, and metabolite concentrations during biomanufacturing, enabling efficient scale-up and adherence to stringent EU and German regulatory standards. This trend is further supported by government initiatives promoting biosimilar adoption to reduce healthcare expenditure.
   
• In 2021, biopharmaceuticals accounted for 32.9 % of total pharmaceutical sales in Germany, and spending on biological medicines reached EURO 16.4 billion, representing roughly one-third of statutory health insurance drug expenditures. These figures underscore the growing importance of biologics and biosimilars in the German healthcare system, creating significant opportunities for bioprocess analyzer manufacturers.
   

Asia Pacific Bioprocess Analyzers Market

The Asia Pacific region is projected to be valued at USD 574.3 million in 2025.
 

• Asia-Pacific is emerging as a dynamic hub for bioprocess analyzers, driven by rapid biopharmaceutical innovation and regulatory acceleration. The National Medical Products Administration (NMPA) in China has significantly streamlined approval timelines, granting 256 new drug approvals between 2019 and 2023, surpassing the U.S. count of 243 in the same period. In 2023 alone, China recorded 104 approvals, including biologics, cell and gene therapies, and vaccines underscoring the region’s growing focus on advanced therapies. This surge in innovative drug clearances is fueling demand for high-performance bioprocess analyzers that ensure precision, compliance, and scalability in biologics manufacturing.
   
• Government-backed funding initiatives further strengthen the market outlook. South Korea’s Korea Drug Development Fund (KDDF) has committed USD 1.6 billion to over 1,200 projects by 2030, while Japan’s Bioventure Support Program is deploying USD 366 million to nurture biotech startups. These investments are accelerating the establishment of cutting-edge biomanufacturing facilities and fostering adoption of analyzers. As Asia-Pacific positions itself as a global biopharma innovation center, the demand for advanced bioprocess analyzers will continue to rise, supported by regulatory harmonization and robust infrastructure development.
   

Japan bioprocess analyzers market is poised to witness lucrative growth between 2026 - 2035.
 

• The Japan market is expanding steadily, driven by the country’s rapidly aging population and the rising prevalence of chronic diseases. Japan has one of the highest proportions of elderly citizens globally, with over 28% of its population aged 65 and above. This demographic shift is increasing the demand for advanced biologics and biosimilars to treat age-related conditions such as cancer, cardiovascular disorders, and autoimmune diseases. Bioprocess analyzers are essential in ensuring the quality and efficiency of biopharmaceutical production, supporting stringent regulatory requirements and enabling manufacturers to meet growing therapeutic needs.
   
• The surge in chronic disease incidence, coupled with government initiatives to promote cost-effective treatments, is accelerating investments in biomanufacturing infrastructure. These factors position Japan as a key market for bioprocess analyzers, with strong growth prospects driven by demographic trends and the increasing burden of chronic illnesses.
   

Latin America Bioprocess Analyzers Market

• Brazil’s market is gaining momentum because of strong government support and surging R&D investments in biotech and pharmaceuticals. Public funding, alongside robust industrial commitment, is fueling domestic capabilities in biologics manufacturing.
   
• Brazil faces a growing chronic disease burden that escalates demand for effective biotherapeutics. According to Brazilian National Health Survey (PNS), in 2019, 23.9 % of adults reported hypertension, 7.7 % had diabetes, and 14.6 % had high cholesterol, while non-communicable diseases (NCDs) accounted for over 70 % of all deaths before age 70. These trends are driving healthcare sectors toward biologics such as monoclonal antibodies and biosimilars, which require precise, scalable manufacturing processes. As producers strive to meet this demand, the need for real-time, automated bioprocess analyzers becomes critical to ensure product consistency, regulatory compliance, and efficient scale-up.
   

Middle East and Africa Bioprocess Analyzers Market

The market in Saudi Arabia is expected to experience significant and promising growth from 2026 to 2035.
 

• The Saudi Arabia market is experiencing strong growth, driven by government initiatives to transform into a regional biotechnology hub. Under Vision 2030, significant investments are being directed toward biomanufacturing infrastructure, research programs, and partnerships with global pharmaceutical companies. These efforts aim to enhance local production of biologics and biosimilars, reduce dependency on imports, and strengthen healthcare resilience. Bioprocess analyzers are integral to this transformation, enabling precise monitoring and control of critical parameters during large-scale biopharmaceutical production.
   
• Consequently, the adoption of bioprocess analyzers is pivotal to Saudi Arabia’s biotechnology ambitions, ensuring quality, efficiency, and scalability in biopharmaceutical production under Vision  2030.
   

Bioprocess Analyzers Market Share

• The top players in the market include F. Hoffmann-La Roche Ltd., Sartorius AG, Danaher Corporation, Thermo Fisher Scientific Inc., and Agilent Technologies, Inc., collectively accounting for 60% of the global market.
   
• These companies dominate through comprehensive product portfolios, advanced process analytical technologies (PAT), and continuous innovation in real-time monitoring and automation solutions for biopharmaceutical manufacturing.
   
• Leading players are aggressively expanding their offerings by introducing integrated systems with automated sampling, AI-driven analytics, and cloud connectivity to support continuous bioprocessing. Agilent Technologies emphasizes automated capillary electrophoresis platforms for protein analysis, while Danaher focuses on scalable PAT solutions for biologics production. Eppendorf is advancing modular bioprocess control systems that combine precision with flexibility for R&D and commercial-scale operations.
   
• Geographic expansion remains a key growth strategy, with major players targeting emerging biopharma hubs in Asia-Pacific and Latin America. Strategic collaborations with biopharmaceutical companies and contract manufacturing organizations (CMOs) further enhance adoption, especially in regions prioritizing local biologics production and digital transformation in manufacturing.
   
• Partnerships enable companies to co-develop advanced process monitoring algorithms and integrate cloud-based analytics for improved process control and regulatory compliance. By combining technological innovation, regional penetration, and customer-centric strategies, these players are positioning themselves for sustained growth in the global market.
   

Bioprocess Analyzers Market Companies

Few of the prominent players operating in the bioprocess analyzers industry include:

• 4BioCell GmbH & Co. KG
• Agilent Technologies, Inc.
• Beckman Coulter Life Sciences
• Danaher Corporation
• Endress+Hauser Group Services AG
• Eppendorf AG
• F. Hoffmann-La Roche Ltd.
• Nova Biomedical
• Randox Laboratories Ltd.
• Sartorius AG
• Solida Biotech GmbH
• SYSBIOTECH GmbH
• Thermo Fisher Scientific Inc.
• Waters Corporation
• Xylem Inc.
   
• Thermo Fisher Scientific

Thermo Fisher Scientific supports bioprocessing with a comprehensive range of single-use bioreactors, mixers, chromatography solutions, process analytics, and automation software, designed to accelerate biologics and cell/gene therapy workflows from R&D through commercial production. Their HyPerforma single-use mixers and Labtainer BioProcess Containers offer scalable and validated platforms that reduce contamination and processing time. Additionally, their TruBio automation and control software enables seamless scale-up and real-time process control.
 

• Sartorius AG

Sartorius delivers advanced Process Analytical Technology (PAT) leveraging inline and online sensors under its BioPAT suite such as BioPAT Spectro (Raman spectroscopy), BioPAT Trace (glucose/lactate monitoring), BioPAT Viamass (automated biomass), and BioPAT Xgas (gas analysis) to enable real-time process monitoring, high data density, and regulatory compliance. These systems are seamlessly integrated into single-use bioreactors like Ambr and Flexsafe for model-driven process development.
 

• Danaher (via Cytiva)

Operating under the Cytiva brand, Danaher offers a robust portfolio of bioprocess monitors and metabolite analyzers that deliver fast, at-line measurements of key parameters including pH, dissolved gases, glucose, and electrolytes for proactive process modeling and control. Their emphasis on Process Analytical Technology (PAT) and intelligent automation supports agile biomanufacturing, with Cytiva's products integrated across upstream and downstream workflows.
 

Bioprocess Analyzers Industry News:

• In May 2023, Cytiva, a subsidiary of Danaher Corporation, merged with Pall Corporation's life sciences division, expanding Cytiva's bioprocessing portfolio. The merger integrated Pall's biotech brands such as Allegro, Supor, and Pegasus with Cytiva's existing offerings like ÄKTA and Xcellerex. This move strengthened Danaher's leadership in life sciences by broadening its bioprocessing capabilities and accelerating therapeutic development.
   
• In January 2023, Nova Biomedical launched the BioProfile FAST CDV, a high-throughput, fully automated analyzer for viable cell density and viability, capable of delivering results in under 70 seconds with just a 100µL sample volume.
   

The bioprocess analyzers market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
• Consumables and accessories

Market, By Analysis Type

• Substrate analysis
• Metabolite analysis
• Concentration detection

Market, By Application

• Antibiotics
• Recombinant proteins
• Biosimilars
• Other applications

Market, By End Use

• Biopharmaceutical companies
• CROs and CMOs
• Research and academic institutes
• Other end use                                                                      

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE